Skip to main content
OpenTrials
Completed

NCT Number: NCT01630928

Renal Sympathetic Denervation and Potential Effects on Glucose Metabolism and Cardiovascular Risk-Factors

The Re-Shape CV-Risk Study is a clinical study where renal adrenergic denervation (RDN) is done in high risk patients with treatment-resistant hypertension. RDN is a mini-invasive, percutaneous technique where an ablation catheter is inserted through a femoral artery into the renal arteries, for destruction of the adrenergic nerve bundles in the artery adventitia by means of radio-frequency ablation. RDN leads to sympathetic denervation of the kidneys, which in the "Symplicity trials" led to an impressive reduction of blood pressure (- 33 /-11 mmHg). In a pilot study, where 40 % of the patients had diabetes, RDN seemed to have beneficial effects not only on blood pressure, but also on insulin sensitivity and hyperinsulinaemia.

The investigators aim to introduce RDN as a clinical study where blood pressure reduction and methodical, technical aspects will be evaluated, but more importantly, also additional effects of RDN on sub-clinical organ damage (endothelial function, vascular stiffness, fundus-, heart-, kidney injury), quality of life, arrhythmia, and glucose metabolism. The investigators hypothesis is that RDN will have positive effect on glucose metabolism, QOL and sub-clinical organ damage.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension, Resistant to Conventional Therapy Cardiovascular Diseases Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Hypertension Resistant to Conventional Therapy Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital of North Norway

Tromsø, N-9038, Norway

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 Years.
  • Resistant hypertension, as defined in the 2007 ESH-ESC guidelines and confirmed by ambulatory or home blood pressure measurements. (Here office BP > 140/90 mmHg on 4 or more antihypertensive drugs in adequate dosages (including one diuretic) or certified drug intolerance).
  • No known secondary reason for hypertension
  • Negative pregnancy test (preferably blood hCG) for female patients of childbearing potential
  • Estimated GFR (glomerular filtration rate) > 45 mL/min/1.73m².
  • Willing and able to comply with follow-up requirements
  • Signed informed consent

Exclusion criteria

  • Type 1 and type 2 diabetes
  • Pregnancy
  • Allergy to the contrast medium used during RDN and Iohexol clearance.
  • Age > 68 years
  • Hemodynamically significant heart valve disease
  • Pacemaker or ICD
  • Medication that may interfere with the procedure (Anticoagulation, Platelet inhibitors, Steroids), if they cannot be temporarily reduced or stopped.
  • Cancer
  • Patients with transplanted kidneys
  • Reno vascular conditions like diameter < 4mm, renal artery stenosis or significant atherosclerosis, previous renal artery stenting

Treatment and study plan

Renal sympathetic denervation

Procedure

This is a mini-invasive trans-catheter procedure with access via a 6F introducer in one of the femoral arteries. The renal sympathetic nerves arise from T10-L2, arborize around the renal artery and primarily lie within the adventitia. A specialized radiofrequency (RF) ablation catheter is introduced into the renal arteries, first one side, then on the other. Usually, 4-6 two-minute treatments per artery using a proprietary RF generator with automated low power and built-in safety algorithms are sufficient to ablate the sympathetic afferent and efferent fibers.

Other names: Symplicity Catheter (Medtronic)

Primary outcomes

  1. Change in blood pressure

    Time frame: from baseline to six months

    Change in blood pressure from baseline to six months after the intervention

  2. Change in blood pressure

    Time frame: from baseline to two years

    Change in blood pressure from baseline to two years after the intervention

Secondary outcomes

  1. Change in quality of Life

    Time frame: From baseline to six months

    The international questionnaires SF-36 and 15-D, with some additional specific questions previously used in international studies will be used for evaluation of RDN effect on symptoms and QOL.

  2. Changes in glucose production and insulin sensitivity

    Time frame: from baseline to six months

    Glucose metabolism will be assessed with oral glucose tolerance test and 2-step euglycemic, hyperinsulinaemic clamp with tracer technique (6,6-2H2-glucose + HOTGINF / measurement of tracer-to-tracee ratio with mass spectrometry): Assessment of endogenous glucose production at fasting condition, at insulin levels around 30 mU/ml (hepatic insulin sensitivity), and at insulin levels of 65-68 mU/ml, imitating the postprandial state (peripheral insulin resistance). Assessment of glucose uptake at these conditions (insulin sensitivity).

  3. Change in quality of Life

    Time frame: From baseline to two years

    The international questionnaires SF-36 and 15-D, with some additional specific questions previously used in international studies will be used for evaluation of RDN effect on symptoms and QOL.

  4. Changes in glucose production and insulin sensitivity

    Time frame: from baseline to two years

    Glucose metabolism will be assessed with oral glucose tolerance test and 2-step euglycemic, hyperinsulinaemic clamp with tracer technique (6,6-2H2-glucose + HOTGINF / measurement of tracer-to-tracee ratio with mass spectrometry): Assessment of endogenous glucose production at fasting condition, at insulin levels around 30 mU/ml (hepatic insulin sensitivity), and at insulin levels of 65-68 mU/ml, imitating the postprandial state (peripheral insulin resistance). Assessment of glucose uptake at these conditions (insulin sensitivity).

  5. Effect of RDN on subclinical organ injury: Myocardium

    Time frame: from baseline to six months

    Long standing hypertension leads to sub-clinical organ damage:

    Myocardial and vascular remodeling measured with echo cardiography. Wall stiffness, left ventricular function, hypertrophy and mass.

  6. Effect of RDN on subclinical organ injury: Myocardium

    Time frame: from baseline to two years

    Long standing hypertension leads to sub-clinical organ damage:

    Myocardial and vascular remodeling measured with echo cardiography. Wall stiffness, left ventricular function, hypertrophy and mass.

  7. Effect of RDN on subclinical organ injury: Retinal vessels

    Time frame: from baseline to six months

    Long standing hypertension leads to sub-clinical organ damage:

    Changes in the microcirculatory vasculature detectable as early changes in retinal vascular caliber or presence of hypertensive retinopathy. High resolution photography (Carl Zeiss Meditec.) and optic coherence tomography of the retina give a direct view to microcirculation. Analyzes will be performed using computer assisted morphometry (IVAN/Retinal Analysis software. Fundus Reading center, University of Wisconsin, Madison USA).

  8. Effect of RDN on subclinical organ injury: Retinal vessels

    Time frame: from baseline to two years

    Long standing hypertension leads to sub-clinical organ damage:

    Changes in the microcirculatory vasculature detectable as early changes in retinal vascular caliber or presence of hypertensive retinopathy. High resolution photography (Carl Zeiss Meditec.) and optic coherence tomography of the retina give a direct view to microcirculation. Analyzes will be performed using computer assisted morphometry (IVAN/Retinal Analysis software. Fundus Reading center, University of Wisconsin, Madison USA).

  9. Effect of RDN on subclinical organ injury: Kidneys

    Time frame: from baseline to six months

    Long standing hypertension leads to sub-clinical organ damage:

    Renal dysfunction. We will measure serum creatinine, cystatin C, GFR (iohexol clearance), albumine/creatinine ratio and N-Acetyl-ß-glucosaminidase (NAG) in morning urine (two different days) before and after RDN. NAG excretion is a sign of tubular injury.

  10. Effect of RDN on subclinical organ injury: Kidneys

    Time frame: from baseline to two years

    Long standing hypertension leads to sub-clinical organ damage:

    Renal dysfunction. We will measure serum creatinine, cystatin C, GFR (iohexol clearance), albumine/creatinine ratio and N-Acetyl-ß-glucosaminidase (NAG) in morning urine (two different days) before and after RDN. NAG excretion is a sign of tubular injury.

  11. Effect of RDN on subclinical organ injury: Endothelial function

    Time frame: from baseline to six months

    Long standing hypertension leads to sub-clinical organ damage:

    Impaired endothelial function; assessed with plethysmography under reactive hyperemia + markers of endothelial dysfunction; Peripheral vasodilator function is measured by digital pulse amplitude tonometry using EndoPAT 2000 (Itamar Medical Ltd., Caesarea, Israel). Reactive hyperemia is produced by applying a blood pressure cuff for 5 min at a pressure of 60 mmHg higher than the systolic pressure on the upper part of the arm.

  12. Effect of RDN on subclinical organ injury: Endothelial function

    Time frame: from baseline to two years

    Long standing hypertension leads to sub-clinical organ damage:

    Impaired endothelial function; assessed with plethysmography under reactive hyperemia + markers of endothelial dysfunction; Peripheral vasodilator function is measured by digital pulse amplitude tonometry using EndoPAT 2000 (Itamar Medical Ltd., Caesarea, Israel). Reactive hyperemia is produced by applying a blood pressure cuff for 5 min at a pressure of 60 mmHg higher than the systolic pressure on the upper part of the arm.

  13. Effect of RDN on subclinical organ injury: Impedance cardiography

    Time frame: from baseline to two years

    Increased central blood pressure measured in ascending aorta, in addition to "augmentation index" (peak aortic pressure increase/pulse pressure) as a measure of vessel compliance, are independent predictors for hypertensive organ injury (brain, heart, kidneys). Aortic wall-stiffness (compliance) and pulse wave reflection are important determinants for central blood pressure and are among the parameters we indirectly will get from impedance cardiography (Hotman System, HEMO SAPIENS INC, Bucharest, Romania)

  14. Effect of RDN on subclinical organ injury: Impedance cardiography

    Time frame: from baseline to six months

    Increased central blood pressure measured in ascending aorta, in addition to "augmentation index" (peak aortic pressure increase/pulse pressure) as a measure of vessel compliance, are independent predictors for hypertensive organ injury (brain, heart, kidneys). Aortic wall-stiffness (compliance) and pulse wave reflection are important determinants for central blood pressure and are among the parameters we indirectly will get from impedance cardiography (Hotman System, HEMO SAPIENS INC, Bucharest, Romania)

Sponsors and collaborators

Lead sponsor

University Hospital of North Norway

Other

Collaborators

  • Odd Berg Medical research Foundation
  • The Royal Norwegian Ministry of Health
  • University of Tromso

Registry information

Official study title

Renal Sympathetic Denervation for Treatment Resistant Hypertension and Potential Effects on Glucose Metabolism and Cardiovascular Risk-Factors (The Re-Shape CV-Risk Study)

Acronym: Re-Shape

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Jun 28, 2012
Registry last updated
May 16, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.